Across 100 patients in three Phase III studies, Vertex's Casgevy showed lasting benefits for more than five years.

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

The HHS and the FDA have been ordered by US District Judge John Bates to restore the webpages on diversity following the court’s ruling.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.